Cite
High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for 'late effects' screening and preventive strategies.
MLA
Samuelson, Clare, et al. “High Prevalence of Cardiovascular and Respiratory Abnormalities in Advanced, Intensively Treated (Transplanted) Myeloma: The Case for ‘Late Effects’ Screening and Preventive Strategies.” Hematology (Amsterdam, Netherlands), vol. 21, no. 5, June 2016, pp. 272–79. EBSCOhost, https://doi.org/10.1080/10245332.2015.1122258.
APA
Samuelson, C., O’Toole, L., Boland, E., Greenfield, D., Ezaydi, Y., Ahmedzai, S. H., & Snowden, J. A. (2016). High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for “late effects” screening and preventive strategies. Hematology (Amsterdam, Netherlands), 21(5), 272–279. https://doi.org/10.1080/10245332.2015.1122258
Chicago
Samuelson, Clare, Laurence O’Toole, Elaine Boland, Diana Greenfield, Yousef Ezaydi, Sam H Ahmedzai, and John A Snowden. 2016. “High Prevalence of Cardiovascular and Respiratory Abnormalities in Advanced, Intensively Treated (Transplanted) Myeloma: The Case for ‘Late Effects’ Screening and Preventive Strategies.” Hematology (Amsterdam, Netherlands) 21 (5): 272–79. doi:10.1080/10245332.2015.1122258.